LAUSR

At present, a large number of curcumin derivatives had been produced and identified aiming to replace the curcumin in view of its low bioavailability and stability. Here, a novel curcumin derivative ZYX02‐Na was first used to reduce the cell viability of human non–small cell lung cells A549, which was confirmed by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide assay. Flow cytometry and Western blot analysis showed that ZYX02‐Na could lead to cell cycle arrest in G0/G1 phase, which demonstrated that ZYX02‐Na inhibited the proliferation of A549 cells. Furthermore, the AMPK/mTOR/4E‐BP1 signaling pathway was activated in ZYX02‐Na‐treated A549 cells. Besides, wounding healing and transwell experiments showed that ZYX02‐Na could also inhibited the migration ability of A549 cells. Moreover, we also found that ZYX02‐Na could induce autophagy of A549 cells by acridine orange staining, GFP‐LC3 subcellular localization observation and Western blotting analysis, respectively. In short, our current studies indicated that ZYX02‐Na possessed the antiproliferation effect and autophagy induction on A549 cells, while in vivo anticancer study of ZYX02‐Na needs to be done in future.